Last Close
Jan 30  •  04:00PM ET
2.10
Dollar change
-0.02
Percentage change
-0.94
%
Index- P/E- EPS (ttm)-2.35 Insider Own11.55% Shs Outstand27.68M Perf Week-3.23%
Market Cap62.17M Forward P/E3.03 EPS next Y0.69 Insider Trans0.00% Shs Float26.18M Perf Month-20.15%
Enterprise Value65.40M PEG- EPS next Q0.01 Inst Own23.71% Short Float13.48% Perf Quarter-31.15%
Income-38.06M P/S259.04 EPS this Y56.03% Inst Trans3.59% Short Ratio3.83 Perf Half Y-21.93%
Sales0.24M P/B- EPS next Y166.72% ROA-391.21% Short Interest3.53M Perf YTD-22.51%
Book/sh-0.93 P/C8.66 EPS next 5Y- ROE- 52W High3.84 -45.31% Perf Year-33.12%
Cash/sh0.24 P/FCF- EPS past 3/5Y68.34% - ROIC- 52W Low1.58 32.91% Perf 3Y-83.59%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin42.56% Volatility5.77% 7.05% Perf 5Y-99.40%
Dividend TTM- EV/Sales272.50 EPS Y/Y TTM-9.32% Oper. Margin-6292.98% ATR (14)0.15 Perf 10Y-
Dividend Ex-Date- Quick Ratio0.29 Sales Y/Y TTM- Profit Margin-15727.69% RSI (14)42.29 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio0.29 EPS Q/Q-79.11% SMA20-6.63% Beta1.91 Target Price36.75
Payout- Debt/Eq- Sales Q/Q- SMA50-8.19% Rel Volume0.41 Prev Close2.12
Employees- LT Debt/Eq- EarningsNov 17 BMO SMA200-21.72% Avg Volume920.42K Price2.10
IPODec 04, 2017 Option/ShortYes / Yes EPS/Sales Surpr.-1236.63% -96.02% Trades Volume380,656 Change-0.94%
Date Action Analyst Rating Change Price Target Change
Sep-08-25Initiated H.C. Wainwright Buy $40
Apr-02-25Initiated BTIG Research Buy $18
Jan-27-26 04:02AM
Jan-16-26 07:03AM
Jan-14-26 07:03AM
Jan-05-26 06:57AM
Dec-18-25 07:05AM
09:23AM Loading…
Dec-08-25 09:23AM
Dec-03-25 02:30PM
07:00AM
Dec-02-25 02:30PM
08:30AM
07:30AM
Dec-01-25 03:30PM
08:03AM
Nov-17-25 04:01PM
03:30PM
08:03AM Loading…
08:03AM
Nov-13-25 03:42PM
Nov-12-25 08:31AM
Nov-10-25 03:15PM
08:03AM
Oct-27-25 02:30PM
Oct-20-25 08:03AM
Oct-17-25 03:00PM
Oct-09-25 02:36PM
Oct-06-25 03:00PM
08:03AM
Sep-30-25 02:30PM
Sep-29-25 08:03AM
Sep-24-25 03:00PM
08:03AM
03:00PM Loading…
Sep-09-25 03:00PM
Sep-08-25 08:17AM
Sep-03-25 03:30PM
08:51AM
08:03AM
Sep-02-25 01:19PM
08:41AM
03:53AM
Aug-27-25 03:00PM
08:03AM
Aug-25-25 03:15PM
Aug-21-25 03:05AM
Aug-19-25 01:00PM
09:21AM
Aug-18-25 09:19AM
08:10AM
Aug-14-25 02:00PM
12:00PM
Aug-13-25 06:06PM
02:00PM
Aug-12-25 03:47PM
Aug-11-25 04:05PM
08:03AM
Aug-08-25 08:03AM
Aug-04-25 08:03AM
Jul-29-25 08:03AM
Jul-21-25 02:37PM
Jul-16-25 03:30PM
Jul-08-25 03:30PM
Jun-30-25 02:30PM
Jun-27-25 11:50AM
Jun-26-25 03:00PM
08:03AM
Jun-23-25 08:03AM
Jun-16-25 02:30PM
08:03AM
Jun-12-25 08:03AM
Jun-06-25 02:30PM
Jun-05-25 02:39PM
08:03AM
May-28-25 03:30PM
May-27-25 07:56PM
02:30PM
May-21-25 12:57PM
08:03AM
May-20-25 01:00PM
May-16-25 01:14PM
03:13AM
May-15-25 04:03PM
02:00PM
10:15AM
May-13-25 02:00PM
08:03AM
May-12-25 08:03AM
May-09-25 11:11AM
May-06-25 09:30AM
08:03AM
May-05-25 08:03AM
Apr-30-25 08:46AM
Apr-21-25 08:01AM
Apr-03-25 08:03AM
Mar-31-25 08:02AM
Mar-27-25 09:55AM
Mar-24-25 08:02AM
Mar-21-25 11:50AM
Mar-18-25 03:01AM
Mar-17-25 08:02AM
Mar-12-25 08:01AM
Mar-01-25 10:29AM
Feb-06-25 08:03AM
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE.